Eric Bjerkholt
CHIEF FINANCIAL OFFICER; Director · 6 filings · Latest: Jun 9, 2026
CERUS CORP
Metagenomi Therapeutics, Inc.
Mirum Pharmaceuticals, Inc.
Surrozen, Inc./DE
| Ticker | Owner | Relationship | Date | Transaction | Cost | #Shares | Value ($) | #Shares Total | SEC Filing |
|---|---|---|---|---|---|---|---|---|---|
CERS | Eric Bjerkholt | Director | Jun 9, 2026 | Sale | $2.60 | 20,454 | $53.2K | 261,679 | |
MIRM | Eric Bjerkholt | CHIEF FINANCIAL OFFICER | Jun 9, 2026 | Option Exercise | $26.49 | 2,393 | $63.4K | 47,181 | |
MIRM | Eric Bjerkholt | CHIEF FINANCIAL OFFICER | Jun 8, 2026 | Sale | $93.82 | 5,000 | $469.1K | 44,788 | |
MIRM | Eric Bjerkholt | CHIEF FINANCIAL OFFICER | Mar 16, 2026 | Sale | $91.98 | 7,287 | $670.2K | 49,788 | |
MIRM | Eric Bjerkholt | CHIEF FINANCIAL OFFICER | Mar 15, 2026 | Option Exercise | — | 13,334 | — | 57,075 |